Medical devices

• US 9,561,311 B2
• Filed: 05/18/2015
• Issued: 02/07/2017
• Est. Priority Date: 12/21/2007
• Status: Active Grant

• Current Assignee: OcuNexus Therapeutics, Inc.
• Original Assignee: CoDa Therapeutics, Inc.
• Inventors: Becker, David Lawrence, Green, Colin Richard, Duft, Bradford James
• Primary Examiner(s): Bowman, Amy
• Application Number:
  US14/715,282
• Publication Number:
  US 20150297804A1
• Time in Patent Office: 631 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/10 Peptides having 12 to 20 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/385 Serum albumin
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61L 17/005 containing a biologically active substance, e.g. a medicament or a biocide
• CPC Class Codes: A61L 2300/25 Peptides having up to 20 amino acids in a defined sequence
• CPC Class Codes: A61L 2300/252 Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/432 Inhibitors, antagonists A61L2300/402 - A61L2300/43 take precedence
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2300/608 having two or more layers
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/08 Materials for coatings
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Abstract

Medical devices comprising an anti-connexin agent suitable for introduction into a subject.

Claims

1. A method of preventing and/or treating inflammation, blood vessel leakage, and/or fibrosis associated with the use or implantation of medical device selected from an ophthalmic implant in a subject comprising introducing into the subject the medical device of which at least a portion comprises an anticonnexin 43 antisense compound releasable upon insertion of the medical device to or within a subject, wherein the inflammation, blood vessel leakage, and/or fibrosis is prevented, ameliorated and/or delayed.

2. The method of claim 1, wherein the ophthalmic implant is a glaucoma shunt.

3. The method of claim 1, wherein the subject is a mammal.

4. The method of claim 1, wherein the mammal is a human.

5. The method of claim 1, wherein the anti-connexin 43 antisense compound decreases connexin 43 protein expression.

6. The method of claim 1, wherein the anti-connexin 43 antisense compound is an oligodeoxynucleotide.

7. The method of claim 1, wherein the anti-connexin 43 antisense compound is a siRNA or RNAi oligonucleotide.

8. The method of claim 1, wherein the anti-connexin 43 antisense compound binds to connexin 43 mRNA.

9. The method of claim 1, wherein the anti-connexin antisense compound binds to a connexin 43 hemichannel.

10. The method of claim 1, wherein the anti-connexin antisense compound binds to a hemichannel extracellular loop.

11. The method of claim 1, wherein the anti-connexin antisense compound is a polynucleotide having a sequence according to SEQ ID NO:

1 or a pharmaceutically acceptable salt thereof.

12. The method of claim 1, wherein the anti-connexin antisense compound is a polynucleotide having a sequence according to SEQ ID NO:

2 or a pharmaceutically acceptable salt thereof.

13. The method of claim 1, wherein the surface of the medical device comprises an anti-connexin antisense compound.

14. The method of claim 13, wherein the anti-connexin antisense compound is present at a weight percentage of about 0.0001% to about 30%.

15. The method of claim 13, wherein the surface of the medical device contacts a target tissue within the subject upon use.

16. The method of claim 1, wherein the release rate of the anti-connexin antisense compound is controlled.

17. The method of claim 1, wherein the medical device provides for surface contact release of the anti-connexin antisense compound.

18. The method of claim 1, wherein the medical device provides for the sustained release of the anti-connexin antisense compound.

19. The method of claim 1, wherein the medical device provides for the slow release of the anti-connexin antisense compound.

20. The method of claim 1, wherein the device comprises a coating containing an anti-connexin antisense compound.

21. The method of claim 20, wherein the coating comprises a polymer.

22. The method of claim 21, wherein the coating comprises a plurality of layers of a polymer/anti-connexin antisense compound mixture.

23. The method of claim 1, wherein the medical device comprises at least one channel formed in an outer surface thereof, and wherein the anti-connexin antisense compound is included on and/or within at least one channel.

24. The method of claim 1, wherein at least a portion of the medical device is formed, in whole or in part, of a substance that includes the anti-connexin antisense compound.

25. The method of claim 1, wherein the device further comprises one or more therapeutic agents.

26. The method of claim 1 or 2, wherein inflammation is prevented or ameliorated.

27. The method of claim 1 or 2, wherein blood vessel leakage is prevented or ameliorated.

28. The method of claim 1 or 2, wherein fibrosis is prevented or ameliorated.

29. The method of claim 6, wherein the anti-connexin 43 antisense oligodeoxynucleotide is chemically unmodified.

30. The method of claim 6, wherein the anti-connexin 43 antisense oligodeoxynucleotide is chemically modified.